newsfilter
← Earnings
Earnings Releases·

Editas Medicine — Third Quarter 2026 Earnings Summary

  • Net loss narrowed to $23.4 million ($0.15 per share) from $25.1 million ($0.28 per share) in the prior year period, driven by a 38.7% increase in collaboration revenues to $10.4 million.
  • Cash and marketable securities rose to $190.2 million as of September 30, 2026, providing sufficient funding for operating and capital expenses through the second half of 2028.
  • EDIT-401 Phase 1/2 Strive study received ethics approval and regulatory clearance in Australia, with patient dosing expected in 2026 and initial safety data anticipated in Q1 2027.
  • A second IND/CTA was accepted for the CD70 HD Allo CAR T program (BMS-986527) in collaboration with Bristol Myers Squibb, triggering a milestone payment.
  • Management appointed Dan Ory, M.D., as Chief Medical Officer in September to oversee clinical development strategy and operations.
Company
EDITAS MEDICINE INC
Sector
Healthcare
Industry
Biotechnology